Small noncoding RNAs (sncRNAs) are a diverse class of RNA molecules that play critical roles in gene regulation, cellular communication, and disease mechanisms. Unlike messenger RNAs (mRNAs), which are translated into proteins, sncRNAs function primarily by interacting with other RNAs or proteins to influence gene expression. However, many of these regulatory molecules remain undetected using traditional RNA sequencing methods due to chemical modifications that interfere with standard sequencing protocols.A research team led by researchers at the Beijing Institute of Genomics has introduced a powerful new method called PANDORA sequencing, designed to uncover a wider range of sncRNAs than ever before. This innovative approach addresses key technical challenges in small RNA sequencing, offering a more comprehensive view of the small RNA landscape.

The Challenge: Why Are Some Small RNAs Hard to Detect?

Standard small RNA sequencing (small RNA-seq) methods rely on preparing RNA libraries for sequencing by adding adapter molecules to the RNA fragments and converting them into complementary DNA (cDNA). However, many sncRNAs have unique chemical modifications at their ends that can block these critical steps, preventing their detection. Specifically, these modifications can:

• Interfere with adapter ligation, making it difficult to attach the necessary sequencing adapters to the RNA molecules.
• Block reverse transcription, which is the process of converting RNA into cDNA for sequencing.
• Lead to biased sequencing results, where only a subset of small RNAs—such as microRNAs (miRNAs)—are reliably detected, while others remain hidden.

This limitation has hindered scientists from fully understanding the diversity and functional importance of sncRNAs in gene regulation, cancer, neurodegenerative diseases, and other biological processes.

How PANDORA Sequencing Works

PANDORA sequencing (or PANDORA-seq) overcomes these barriers by introducing a specialized enzymatic treatment before sequencing. The key innovation in this method is the sequential use of two enzymes:

1. T4 Polynucleotide Kinase (T4PNK): This enzyme modifies RNA molecules by adding or removing phosphate groups at their ends, making them more suitable for adapter ligation.
2. AlkB (a bacterial demethylase): This enzyme removes RNA modifications that would otherwise block reverse transcription, allowing for more efficient cDNA synthesis.

By using this two-step enzymatic treatment, PANDORA-seq ensures that previously undetectable sncRNAs can now be sequenced. Once the RNA is processed, the method uses deep sequencing and a specialized bioinformatics tool called SPORTS to analyze the resulting data. SPORTS enables researchers to:

• Identify sncRNAs derived from a variety of parental RNA molecules, such as transfer RNA (tRNA) and ribosomal RNA (rRNA).
• Determine the precise locations within these parental RNAs from which the sncRNAs originate.
• Expand the catalog of known sncRNAs, revealing previously unknown players in gene regulation.

Overview of the PANDORA-seq protocol

a, A schematic representation of RNA preparation and library construction steps. Different colors represent RNAs with different RT-blocking modifications and different termini. b, A schematic representation of the data analysis pipeline for small RNA analysis using the SPORTS 1.1 pipeline. ncRNA, non-coding RNA.

What This Means for RNA Research

By eliminating the sequencing bias that has traditionally favored well-characterized small RNAs like miRNAs, PANDORA-seq provides researchers with a more complete and unbiased view of the small RNA transcriptome. This has several important implications:

1. Discovering New Regulatory RNAs: Many sncRNAs remain unexplored due to technical limitations. PANDORA-seq can help uncover novel RNA molecules with important regulatory functions.
2. Understanding Disease Mechanisms: Small RNAs are known to play roles in cancer, neurodegeneration, and immune system function. By identifying previously undetectable sncRNAs, researchers can better understand their contributions to disease.
3. Enhancing Therapeutic Development: RNA-based therapies, including small RNA mimics and inhibitors, are emerging in medicine. A more complete small RNA catalog could lead to new drug targets and therapeutic strategies.

Conclusion

PANDORA sequencing represents a significant breakthrough in transcriptomics, allowing scientists to study a more diverse set of small RNAs than ever before. By removing technical obstacles that have long limited RNA sequencing, this method opens new doors for discovering regulatory RNAs with critical roles in health and disease. As researchers continue to explore the small RNA world with PANDORA-seq, we can expect exciting new insights into gene regulation, cellular function, and potential therapeutic targets.